All In Biotech

Drug Trial Radar · NCT00471094

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.

Last checked: Nov 19, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 831 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

831

Actual

Start

May 2007

Primary completion

Oct 2007

Study completion Oct 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 9, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.

Conditions

  • Esophagitis

Interventions

  • IlaprazoleDrug

    Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.

  • IlaprazoleDrug

    Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.

  • IlaprazoleDrug

    Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.

  • LansoprazoleDrug

    Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The crude healing rate of Erosive Esophagitis at week 4 of treatment as assessed by endoscopy.Time frame: Week 4

Locations

94 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hueytown, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Sherwood, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Cypress, California

  • Site not named

    Encinitas, California

  • Site not named

    Garden Grove, California

  • Site not named

    Irvine, California

  • Site not named

    Lancaster, California

  • Site not named

    Mission Hills, California

  • Site not named

    Oakland, California

  • Site not named

    Orange, California

  • Site not named

    Pasadena, California

  • Site not named

    San Diego, California

  • Site not named

    West Covina, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Longmont, Colorado

  • Site not named

    Pueblo, Colorado

  • Site not named

    Bristol, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Longwood, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Smyrna Beach, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Conyers, Georgia

  • Site not named

    Newnan, Georgia

  • Site not named

    Tucker, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Moline, Illinois

  • Site not named

    Rockford, Illinois

  • Site not named

    Clive, Iowa

  • Site not named

    Davenport, Iowa

  • Site not named

    Dubuque, Iowa

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.